Zamtoacabtagene Autoleucel External Comparator Study
Research type
Research Study
Full title
Zamtoacabtagene Autoleucel External Comparator Study
IRAS ID
367595
Contact name
Kim Linton
Contact email
Sponsor organisation
Miltenyi Biomedicine GmbH
Duration of Study in the UK
0 years, 6 months, 29 days
Research summary
Large B-cell lymphoma (LBCL) is a group of fast-growing blood cancers, with diffuse large B-cell lymphoma (DLBCL) being the most common and aggressive type. For many years, the standard treatment has been a combination of chemotherapy drugs known as R-CHOP. However, this treatment doesn’t work for everyone—up to half of patients either don’t respond or their cancer comes back, leading to poor outcomes.
A newer type of treatment called CAR-T cell therapy has brought major improvements for patients whose DLBCL has returned or hasn’t responded to earlier treatments, especially when used as a third option.This study is a retrospective, data-only project. It does not involve any new treatment or drug administration. Instead, it looks back at existing medical records to collect information on how patients with DLBCL have been treated in the past. The aim is to compare outcomes from these real-world patients with those from separate clinical trials (DALY 2-EU and DALY II USA), which tested a CAR-T therapy called zamto-cel.
By comparing these different groups, the study hopes to better understand how effective zamto-cel is in real-world settings and help improve future treatment options for people with this type of lymphoma.REC name
North of Scotland Research Ethics Committee 2
REC reference
26/NS/0040
Date of REC Opinion
7 May 2026
REC opinion
Favourable Opinion